OSIVAX appoints Dr. W. Ripley Ballou (M.D) as member of its Clinical Advisory Board

Rip Ballou’s appointment will strengthen OSIVAX’s ambition to develop a pipeline of disruptive vaccines against infectious diseases.

Lyon, France – September 22, 2021 – OSIVAX, a biopharmaceutical company focused on the development of “universal” vaccines against mutating viruses, including influenza and coronaviruses, announced today the appointment of Dr. Ripley Ballou (MD) as member of its Clinical Advisory Board.

« We welcome Dr. Ballou to our clinical board. » commented Alexandre Le Vert, CEO and cofounder of OSIVAX. « We look forward to his contribution as we advance our portfolio of T-cell based vaccines, including our broad-spectrum influenza candidate OVX836 through key clinical studies. Rip is a highly regarded leader in the field of vaccine development and his insights will help us to efficiently move our clinical programs forward. »

Dr. Ballou brings over 30 years of industry executive experience with broad background across research and all phases of vaccine clinical development in multiple therapeutic areas. He currently serves as Principal Investigator for the ADVANCE Program at IAVI, a nonprofit scientific research organization to addressing high unmet global health challenges. Prior to his current role, Rip held senior leadership positions at GSK Vaccines R&D for 15 years. Most recently, he was the head of GSK global vaccines R&D center in Rockville, Maryland, and before that he was leading the Global Clinical R&D team. Previously he served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health at the Bill & Melinda Gates Foundation, held senior leadership positions in MedImmune Vaccine and led the department of immunology in the Division of Communicable diseases and Immunology at the Walter Reed Army Institute of Research.

« OSIVAX is addressing a number of globally challenging infectious diseases with its disruptive technology platform. I am excited to bring my experience to advance their vaccine portfolio candidates through the next clinical phases », said Dr. Rip Ballou. 

OSIVAX’s mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.  

For further information: www.osivax.com

Alexandre LE VERT, CEO
+33 (0)9 70 30 13 80

For Media Inquiries
Trophic Communications
Gretchen Schweitzer or Valeria Fisher
schweitzer@trophic.eu or fisher@trophic.eu
+49 (0) 172 861 8540 +49 (0) 175 804 1816